Feature | January 24, 2013

Study Supports Use of Laser Atherectomy for Peripheral In-Stent Restenosis

Results provide basis for landmark EXCITE ISR trial underway in United States

Spectranetics Peripheral Artery Disease Laser Atherectomy

January 24, 2013 — The Spectranetics Corporation announced final results from the PATENT (Photo-Ablation using the TURBO-Booster(R) and Excimer Laser for In-Stent Restenosis Treatment) clinical study evaluating the safety and efficacy of the Spectranetics peripheral laser atherectomy catheters for the treatment of in-stent restenosis (ISR) in the femoropopliteal artery in the leg. ISR occurs as a result of narrowing of the artery in patients who have undergone stenting for the treatment of peripheral arterial disease (PAD). There is currently no U.S. Food and Drug Administration (FDA)-cleared or approved device to treat peripheral in-stent restenosis, which remains a major unsolved medical problem.

Ninety patients participated in this prospective, multi-center registry, which completed enrollment in December 2011 at five centers in Germany. The study evaluated extremely complex patients who had a previously failed stent procedure to address peripheral arterial disease.

Final results presented by Professor Thomas Zeller (Herz-Zentrum Bad Krozingen, Germany) at the Leipzig Interventional Course (LINC) 2013 in Leipzig, Germany, indicate 82 percent and 52 percent freedom from target lesion revascularization (TLR) at six and 12 months, respectively. Laser atherectomy demonstrated excellent midterm primary patency of 64 percent as compared to 37 percent with balloon angioplasty primary patency as published in previous clinical registries. This is a significant improvement considering the challenging nature of these patients.

In the PATENT Study, percent diameter stenosis was reduced from 87.1 percent to 7.5 percent post-laser atherectomy and balloon angioplasty as measured by the angiographic core lab. Procedural success rate, defined as achievement of less than or equal to 30 percent final residual restenosis, was 98.9 percent, and cumulative major adverse events (MAEs) were 2.2 percent from procedure through 30 days following the procedure. Patients saw significant and sustained improvement in ankle brachial index (ABI) and walking ability throughout the study. Laser atherectomy in ISR lesions also preserved excellent stent integrity throughout the duration of the study.

"The PATENT study demonstrates that with laser atherectomy, excellent acute results can be achieved and the underlying stent is not damaged. The patency and TLR rate seem to be significantly better compared to balloon-angioplasty, the current standard treatment of ISR," said Andrej Schmidt of Park Hospital, Leipzig Germany and principal investigator for PATENT.

Notably, the freedom from TLR rate within the PATENT study exceeds the targeted rate in the randomized, controlled EXCITE ISR (EXCImer Laser Randomized Controlled Study for Treatment of Femoropopliteal In-Stent Restenosis) trial, a landmark study currently underway in the United States, providing confidence in the EXCITE ISR trial design.

The EXCITE ISR trial will enroll up to 353 patients with chronic PAD associated with femoropopliteal in-stent restenosis at up to 35 centers in the United States. Patients are randomized in a 2:1 allocation to either laser atherectomy with adjunctive balloon angioplasty or balloon angioplasty alone. The study is designed to show superiority of laser atherectomy plus adjunctive balloon angioplasty for the primary efficacy endpoint of freedom from TLR.

"We are very encouraged by the PATENT results. This is a significant step forward in a compelling body of evidence that proves the safety and efficacy of laser atherectomy in treating in-stent restenosis. Successfully treating ISR represents an inflection point in our growth trajectory. This market is more than twice as large as the worldwide atherectomy market," said Scott Drake, CEO of Spectranetics.

The PATENT study population included patients with disease severity ranging from intermittent claudication to critical limb ischemia(Rutherford class 2-5). Lesions ranged from 1 cm to 25 cm with averagetotal lesion length of 12.3cm, and 93 percent were in the superficial femoralartery (SFA). Nearly 34 percent of patients had total occlusions. Fiftypercent of patients were diabetics, and 36 percent had previously been treated for in-stent restenosis using other therapies.

Spectranetics is also supporting a physician-initiated pilot study at four centers in Europe evaluating the use of laser atherectomy followed by a paclitaxel-coated angioplasty balloon (PTX PTA) compared with the use of PTX PTA alone in the treatment of in-stent lesions in above-the-knee arteries. Enrollment of 50 patients is expected to be completed in the first half of 2013. Spectranetics' support of the PHOTOPAC (Photoablation Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis in In-stent Femoropopliteal Obstructions) trial is in the form of an unrestricted research grant.

"The midterm patency with laser atherectomy for ISR lesions in the PATENT study is encouraging. We look forward to additional data on the combination of debulking with laser followed by local drug delivery," said Professor Thomas Zeller, a co-principal investigator of PHOTOPAC.

For more information: www.spectranetics.com

Related Content

cardiac surgery, simulation training, University of Washington, case studies

Multiple repetitions of bypass grafts on a heart, using the Ramphal simulator. Courtesy of the University of Washington in Seattle.

News | Cardiovascular Surgery| August 25, 2016
August 25, 2016 — Simulation training fo
aortic dissection, family history, same age, clinical study, John A. Elefteriades, Annals of Thoracic Surgery
News | Structural Heart| August 25, 2016
People with a family member who had an aortic dissection — a spontaneous tear in one of the body’s main arteries —...
nanoparticles, blood clotting, internal bleeding, American Chemical Society study, Erin B. Lavik

Nanoparticles (green) help form clots in an injured liver. The researchers added color to the scanning electron microscopy image after it was taken. Image courtesy of Erin Lavik, Ph.D.

News | Hemostasis Management| August 24, 2016
August 24, 2016 — Whether severe trauma occurs on the battlefield or the highway, saving lives often comes down to...
Intact Vascular, TOBA clinical study, one-year results, Tack Endovascular System, Journal of Vascular Surgery
News | Peripheral Arterial Disease (PAD)| August 24, 2016
Intact Vascular Inc. announced that the one-year results from its Tack Optimized Balloon Angioplasty (TOBA) clinical...
Technavio report, renal denervation devices, 2015
News | Renal Denervation| August 23, 2016
August 23, 2016 — Technavio analysts forecast the global...
News | Heart Failure| August 23, 2016
August 23, 2016 — A new study of more than 13,000 people has found that so-called morbid obesity appears to stand alo
Jason Burdick, injectable hydrogels, heart failure, heart attack, American Chemical Society

Compared to other types of hydrogels being developed (left), a new hydrogel (right) can form crosslinks after injection into the heart, making the material stiffer and longer-lasting. Image courtesy of American Chemical Society.

News | Heart Failure| August 23, 2016
August 23, 2016 — During a heart attack, clots or narrowed arteries block blood flow, harming or killing cells within
News | Peripheral Arterial Disease (PAD)| August 22, 2016
Avinger Inc. recently announced the closing of its previously announced public offering of 9,857,800 shares of Avinger’...
sleep apnea, hypertension, clinical study, Science Signaling, University of Chicago
News | Hypertension| August 22, 2016
Obstructive sleep apnea is a common cause of high blood pressure. In the Aug. 17, 2016, issue of the journal Science...
DMC Heart Hospital, Detroit Medical Center, complex percutaneous intervention education course, PCI, cath lab training
News | Cath Lab| August 22, 2016
The Detroit Medical Center (DMC) Heart Hospital recently completed a Complex Percutaneous Intervention education course...
Overlay Init